151 related articles for article (PubMed ID: 28877353)
1. Adolescence transitional care in neurogenic detrusor overactivity and the use of OnabotulinumtoxinA: A clinical algorithm from an Italian consensus statement.
Palleschi G; Mosiello G; Iacovelli V; Musco S; Del Popolo G; Giannantoni A; Carbone A; Carone R; Tubaro A; De Gennaro M; Marte A; Finazzi Agrò E
Neurourol Urodyn; 2018 Mar; 37(3):904-915. PubMed ID: 28877353
[TBL] [Abstract][Full Text] [Related]
2. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
4. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
5. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
6. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
7. Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity.
Leitner L; Walter M; Freund P; Mehnert U; Michels L; Kollias S; Kessler TM
BMC Urol; 2014 Aug; 14():68. PubMed ID: 25132340
[TBL] [Abstract][Full Text] [Related]
8. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Gamé X; Mouracade P; Chartier-Kastler E; Viehweger E; Moog R; Amarenco G; Denys P; De Seze M; Haab F; Karsenty G; Kerdraon J; Perrouin-Verbe B; Ruffion A; Soler JM; Saussine C
J Pediatr Urol; 2009 Jun; 5(3):156-64. PubMed ID: 19264554
[TBL] [Abstract][Full Text] [Related]
10. Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
Khavari R; Elias SN; Pande R; Wu KM; Boone TB; Karmonik C
J Urol; 2019 Jan; 201(1):135-140. PubMed ID: 30076906
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
12. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
Ellsworth P; Travis M
Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.
Karsenty G; Denys P; Amarenco G; De Seze M; Gamé X; Haab F; Kerdraon J; Perrouin-Verbe B; Ruffion A; Saussine C; Soler JM; Schurch B; Chartier-Kastler E
Eur Urol; 2008 Feb; 53(2):275-87. PubMed ID: 17988791
[TBL] [Abstract][Full Text] [Related]
14. How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA.
Przydacz M; Golabek T; Chlosta P
Adv Clin Exp Med; 2019 Apr; 28(4):555-567. PubMed ID: 30729759
[TBL] [Abstract][Full Text] [Related]
15. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
Avallone MA; Sack BS; El-Arabi A; Guralnick ML; O'Connor RC
Neurourol Urodyn; 2017 Apr; 36(4):1104-1107. PubMed ID: 27283922
[TBL] [Abstract][Full Text] [Related]
16. Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA.
Shreck E; Gioia K; Lucioni A
Curr Urol Rep; 2016 Apr; 17(4):27. PubMed ID: 26902621
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of onobotulinumtoxinA as a therapeutic option for pediatric neurogenic detrusor overactivity.
Peard LM; Pope JC; Dmochowski R
Expert Rev Neurother; 2023; 23(9):763-774. PubMed ID: 37556757
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
Chen SF; Chang CH; Kuo HC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
Kennelly M; Dmochowski R; Schulte-Baukloh H; Ethans K; Del Popolo G; Moore C; Jenkins B; Guard S; Zheng Y; Karsenty G;
Neurourol Urodyn; 2017 Feb; 36(2):368-375. PubMed ID: 26607743
[TBL] [Abstract][Full Text] [Related]
20. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?
Pistolesi D; Giannarini G; Stampacchia G; Selli C
Eur Urol; 2011 Oct; 60(4):872-3. PubMed ID: 21802198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
